Taiho Oncology

Subsidiary of Otsuka Holdings (4578)

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Approved
Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Small molecule
Acute Myeloid LeukemiaMyelodysplastic Syndromes

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Decitabine/cedazuridine (Inqovi)Phase 2Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Est. primary completion 2027-12-31 · NCT04093570 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

27 February 2027FDA action dateZipalertinibPDUFA target action date for zipalertinib NDA
US, FDA · FDA · Source ↗

Recent

28 April 2026Filing acceptedZipalertinibFDA accepts NDA for zipalertinib (previously treated EGFR ex20ins NSCLC)
US, FDA · Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics · Source ↗

Financial reports

No financial reports recorded.